Bioliography
- EISEN HJ, TUZCU EM, DORENT R et al.: Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. N Engl. Med. (2003) 349:847–858.
- KECK BM, BENNET LE, ROSENDALE J et al.: World-wide thoracic organ transplantation: a report from the UNOS/ISHRLT international registry for thoracic organ transplantation. Cilia. Transpl. (1999) 13:35–49.
- JULIUS BK, ATTENHOFER JOST CH, SUTSCH G et al.: Incidence, progression and functional significance of cardiac allograft vasculopathy after heart transplantation. Transplantation (2000) 69:847–853.
- SCHULER W, SEDRANI R, COTTENS S et al.: SDZ PAD, a new rapamycin derivative: pharmacological properties in vitro and in vivo. Transplantation (1997) 64:36–42.
- SCHUURMAN HJ, COTTENS S, FUCHS S et al.: SDZ PAD, a new rapamycin derivative: synergism with cyclosporine. Transplantation (1997) 64:32–35.
- NEUMAYER HH, PARADIS K, KORN A et al.: Entry-into-human study with the novel immunosuppressant SDZ PAD in stable renal transplant recipients. Br. Cilia. Pliannacol (1999) 48:694–703.
- KAHAN BD, KAPLAN B, LORBER MI et al.: PAD in de novo renal transplantation: comparison of three doses on the incidence and severity of acute rejection. Transplantation (2001) 71:1400–1406.
- HOYER PF, ETTENGER R, KOVARIK JM et al: Everolimus in pediatric de nova renal transplant patients. Transplantation (2003) 75:2082–2085.
- KOVARIK JM, EISEN H, DORENT R et al.: Everolimus in de novo cardiac transplantation: pharmacokinetics, therapeutic range, and influence on cyclosporine exposure. Heart Lung Transplant. (2003) 22:1117-1125. Affiliation Sheila A Doggrell PhD DSc Doggrell Biomedical Communications, 47 Caronia Crescent, Lynfield, Auckland, New Zealand E-mail: [email protected]